eligibility_summary
Eligibility: HIV+ adults 18–75 with CD20+ DLBCL (de novo or transformed), ECOG ≤2, PET‑measurable disease per Lugano, adequate hepatic/renal function (CrCl ≥30) and blood counts (no recent transfusions), consent, and fit for study. Exclude CNS lymphoma, active autoimmune disease or recent systemic steroids/immunosuppression, major cardiac disease (LVEF <50%, recent MI, CHF III–IV), prior selinexor, severe allergy, transplant, other active cancers (except cured ≥5y, BCC, cervical in situ), recent ≥G2 neurotoxicity, severe infection, or conditions compromising safety.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Single-arm Phase 4 trial in relapsed/refractory DLBCL evaluates selinexor plus R-GemOx. Selinexor (oral small-molecule SINE) inhibits XPO1/CRM1, retaining tumor-suppressor proteins (e.g., p53, FOXO) in the nucleus, suppressing NF-κB/oncogenic signaling, and inducing apoptosis. Rituximab (chimeric anti-CD20 monoclonal antibody) depletes B cells via ADCC, CDC, and apoptosis. Gemcitabine (nucleoside analog antimetabolite) inhibits DNA synthesis via ribonucleotide reductase inhibition and chain termination. Oxaliplatin (platinum agent) forms DNA crosslinks causing damage and cell death. Targets/pathways: CD20+ malignant B cells, XPO1-dependent nuclear export, DNA replication/repair, NF-κB and tumor-suppressor pathways.